Notice: This CMS-approved document has been submitted - Philips ...
Notice: This CMS-approved document has been submitted - Philips ... Notice: This CMS-approved document has been submitted - Philips ...
CMS-1403-FC TABLE 51: Impact of CY 2009 Changes in Payments to Hospital-Based and Independent ESRD Facilities [Percent change in composite rate payments to ESRD facilities (both program and beneficiaries)] 1058 1 2 3 4 5 6 7 Number Of facilities Number of Dialysis Treatments (in millions) Effect of Changes in Wage Index 1 / Effect of of the MIPPA provisions only 2 / Overall effect without drug add-on 3 / By Region New England 154 1.2 1.2 0.5 1.8 1.5 Middle Atlantic 566 4.6 0.1 0.2 0.3 0.0 East North Central 768 5.8 -1.0 0.6 -0.4 -0.7 West North Central 372 2.0 0.0 0.3 0.3 0.0 South Atlantic 1104 8.3 -0.1 0.8 0.8 0.5 East South Central 379 2.7 -1.0 0.9 0.0 -0.3 West South Central 667 5.2 -0.5 0.9 0.3 0.1 Mountain 259 1.6 0.0 0.7 0.7 0.5 Pacific 555 4.6 2.2 0.8 3.0 2.7 Puerto Rico & Virgin Islands 34 0.4 -4.6 0.8 -3.8 -4.1 1/This column shows the overall effect of wage index changes on ESRD providers. Composite rate payments computed using the current wage index are compared to composite rate payments using the CY 2009 wage index changes. This column does not include the drug add-on to the composite rate. 2/This column shows the effect of the MIPPA provisions which include a 1 percent increase to composite rate and elimination of separate composite rate for hospital-based ESRD providers. These provisions are effective January 1, 2009. This column does not include the drug add-on to the composite rate. 3/This column shows the percent change between CY 2009 and CY 2008 composite rate payments to ESRD facilities. This column does not include the drug add-on to the composite rate. Overall effect including drug add-on 4 / All Providers 4,858 36.4 0.0 0.7 0.7 0.4 Independent 4,303 32.8 0.0 1.0 1.0 0.7 Hospital Based 555 3.7 0.2 -2.1 -1.9 -2.1 By Facility Size Less than 5000 treatments 1,732 5.0 -0.1 0.6 0.5 0.2 5000 to 9999 treatments 1,915 13.9 0.0 0.8 0.8 0.5 Greater than 9999 treatments 1,211 17.6 0.0 0.6 0.6 0.4 Type of Ownership Profit 3,932 29.8 0.0 1.0 0.9 0.7 Nonprofit 926 6.6 0.2 -0.7 -0.5 -0.7 By Geographic Location Rural 1,320 7.6 -0.5 0.6 0.1 -0.1 Urban 3,538 28.8 0.1 0.7 0.8 0.5
CMS-1403-FC 1059 4/This column shows the percent change between CY 2009 and CY 2008 composite rate payments to ESRD facilities. The CY 2009 payments include the CY 2009 wage adjusted composite rate, and the 15.2 percent drug add-on times treatments The CY 2008 payments to ESRD facilities includes the CY 2008 wage adjusted composite rate and the 15.5 percent drug add-on times treatments. G. IDTF Issues We believe that the provisions regarding IDTFs as discussed in Section II.I. of this final rule with comment period will have minimal budgetary impact. We believe that the IDTF enrollment provisions contained in this rule are necessary and will help ensure that beneficiaries receive quality care by making certain that those entities providing mobile diagnostic testing services meet established performance standards and are enrolled in the Medicare program as IDTFs. We maintain that that most of these mobile units providing diagnostic testing services are already enrolled as IDTFs as required in §410.33(g), however we have no way of determining how many of these units are providing mobile diagnostic testing services, yet are not enrolled. We do not believe that beneficiary access to IDTF services will be affected by these requiring mobile units providing diagnostic testing services to enroll in the Medicare program. H. Physician and Nonphysician Practitioner Enrollment Issues
- Page 1007 and 1008: CMS-1403-FC Section 144(b) of the M
- Page 1009 and 1010: CMS-1403-FC rulemaking with respect
- Page 1011 and 1012: CMS-1403-FC (respectively) of this
- Page 1013 and 1014: CMS-1403-FC completing and submitti
- Page 1015 and 1016: CMS-1403-FC §424.516(d)(1). Additi
- Page 1017 and 1018: CMS-1403-FC to several associated i
- Page 1019 and 1020: CMS-1403-FC incentive payment for 2
- Page 1021 and 1022: CMS-1403-FC year of PQRI reporting)
- Page 1023 and 1024: CMS-1403-FC Based on the assumption
- Page 1025 and 1026: CMS-1403-FC these activities for th
- Page 1027 and 1028: CMS-1403-FC per hour, we estimate t
- Page 1029 and 1030: CMS-1403-FC Because of the large nu
- Page 1031 and 1032: CMS-1403-FC threshold, and hence al
- Page 1033 and 1034: CMS-1403-FC shoes, the regulation i
- Page 1035 and 1036: CMS-1403-FC with comment period for
- Page 1037 and 1038: CMS-1403-FC substance of State laws
- Page 1039 and 1040: CMS-1403-FC $20 million from what e
- Page 1041 and 1042: CMS-1403-FC ● Impact of Work RVU
- Page 1043 and 1044: CMS-1403-FC imaging services from t
- Page 1045 and 1046: CMS-1403-FC ● Impact of section 1
- Page 1047 and 1048: CMS-1403-FC management, could have
- Page 1049 and 1050: CMS-1403-FC Table 50 illustrates, f
- Page 1051 and 1052: CMS-1403-FC CPT/ HCPCS Mod Descript
- Page 1053 and 1054: CMS-1403-FC impact associated with
- Page 1055 and 1056: CMS-1403-FC The fourth column shows
- Page 1057: CMS-1403-FC the CY 2007 claims. The
- Page 1061 and 1062: CMS-1403-FC requirements is to allo
- Page 1063 and 1064: CMS-1403-FC This amendment of the e
- Page 1065 and 1066: CMS-1403-FC 4 minutes per call, lab
- Page 1067 and 1068: CMS-1403-FC e-prescribing and who m
- Page 1069 and 1070: CMS-1403-FC anti-markup provisions
- Page 1071 and 1072: CMS-1403-FC approximately $50 per h
- Page 1073 and 1074: CMS-1403-FC e-prescribing measure i
- Page 1075 and 1076: CMS-1403-FC we estimate that each e
- Page 1077 and 1078: CMS-1403-FC P. Prohibition Concerni
- Page 1079 and 1080: CMS-1403-FC that provides a calcula
- Page 1081 and 1082: CMS-1403-FC treatment) that occur a
- Page 1083 and 1084: CMS-1403-FC locality (+5.37 percent
- Page 1085 and 1086: CMS-1403-FC additional rental payme
- Page 1087 and 1088: CMS-1403-FC T. Competitive Acquisit
- Page 1089 and 1090: CMS-1403-FC Program; II.T. Electron
- Page 1091 and 1092: CMS-1403-FC which means that in 200
- Page 1093 and 1094: CMS-1403-FC List of Subjects 42 CFR
- Page 1095 and 1096: CMS-1403-FC For the reasons set for
- Page 1097 and 1098: CMS-1403-FC (1) Except as specified
- Page 1099 and 1100: CMS-1403-FC pressure, a visual acui
- Page 1101 and 1102: CMS-1403-FC (ii) A speech-language
- Page 1103 and 1104: CMS-1403-FC during the hours that t
- Page 1105 and 1106: CMS-1403-FC (i) Be certified as a n
- Page 1107 and 1108: CMS-1403-FC 14. Section 410.155 is
<strong>CMS</strong>-1403-FC<br />
TABLE 51: Impact of CY 2009 Changes in Payments to<br />
Hospital-Based and Independent ESRD Facilities<br />
[Percent change in composite rate payments to ESRD facilities (both<br />
program and beneficiaries)]<br />
1058<br />
1 2 3 4 5 6 7<br />
Number<br />
Of<br />
facilities<br />
Number of<br />
Dialysis<br />
Treatments<br />
(in<br />
millions)<br />
Effect of<br />
Changes<br />
in Wage<br />
Index 1 /<br />
Effect of<br />
of the<br />
MIPPA<br />
provisions<br />
only 2 /<br />
Overall<br />
effect<br />
without<br />
drug<br />
add-on 3 /<br />
By Region<br />
New England 154 1.2 1.2 0.5 1.8 1.5<br />
Middle Atlantic 566 4.6 0.1 0.2 0.3 0.0<br />
East North Central 768 5.8 -1.0 0.6 -0.4 -0.7<br />
West North Central 372 2.0 0.0 0.3 0.3 0.0<br />
South Atlantic 1104 8.3 -0.1 0.8 0.8 0.5<br />
East South Central 379 2.7 -1.0 0.9 0.0 -0.3<br />
West South Central 667 5.2 -0.5 0.9 0.3 0.1<br />
Mountain 259 1.6 0.0 0.7 0.7 0.5<br />
Pacific 555 4.6 2.2 0.8 3.0 2.7<br />
Puerto Rico & Virgin Islands 34 0.4 -4.6 0.8 -3.8 -4.1<br />
1/<strong>This</strong> column shows the overall effect of wage index changes on ESRD providers. Composite rate<br />
payments computed using the current wage index are compared to composite rate payments using the<br />
CY 2009 wage index changes. <strong>This</strong> column does not include the drug add-on to the composite rate.<br />
2/<strong>This</strong> column shows the effect of the MIPPA provisions which include a 1 percent increase to composite<br />
rate and elimination of separate composite rate for hospital-based ESRD providers. These provisions are<br />
effective January 1, 2009. <strong>This</strong> column does not include the drug add-on to the composite rate.<br />
3/<strong>This</strong> column shows the percent change between CY 2009 and CY 2008 composite rate payments to<br />
ESRD facilities. <strong>This</strong> column does not include the drug add-on to the composite rate.<br />
Overall<br />
effect<br />
including<br />
drug<br />
add-on 4 /<br />
All Providers 4,858 36.4 0.0 0.7 0.7 0.4<br />
Independent 4,303 32.8 0.0 1.0 1.0 0.7<br />
Hospital Based 555 3.7 0.2 -2.1 -1.9 -2.1<br />
By Facility Size<br />
Less than 5000 treatments 1,732 5.0 -0.1 0.6 0.5 0.2<br />
5000 to 9999 treatments 1,915 13.9 0.0 0.8 0.8 0.5<br />
Greater than 9999 treatments 1,211 17.6 0.0 0.6 0.6 0.4<br />
Type of Ownership<br />
Profit 3,932 29.8 0.0 1.0 0.9 0.7<br />
Nonprofit 926 6.6 0.2 -0.7 -0.5 -0.7<br />
By Geographic Location<br />
Rural 1,320 7.6 -0.5 0.6 0.1 -0.1<br />
Urban 3,538 28.8 0.1 0.7 0.8 0.5